Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2008-07-24
2011-10-18
Habte, Kahsay T (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S364400, C548S364100, C548S377100
Reexamination Certificate
active
08039502
ABSTRACT:
A new class of phosphoinositide-dependent kinase-1 (PDK-1) inhibitors of Formula I:wherein X wherein X is —CF3, Ar is selected fromand R is selected fromwhereR′ is L-Lys, D-Lys, β-Ala, L-Lue, L-Ile, Phe, SO2CH2CH2NH2, SO2NH2, Asn, Glu or Gyl, andR″ is methyl, ethyl, allyl, CH2CH2OH, CH2CN, CH2CH2CN, CH2CONH2,
REFERENCES:
patent: 5091387 (1992-02-01), Evans et al.
patent: 5134142 (1992-07-01), Matsuo
patent: 5206240 (1993-04-01), Baldwin et al.
patent: 5466823 (1995-11-01), Talley
patent: 5521207 (1996-05-01), Graneto
patent: 5550147 (1996-08-01), Matsuo
patent: 5639777 (1997-06-01), Lee
patent: 5670509 (1997-09-01), Evans et al.
patent: 5760068 (1998-06-01), Talley
patent: 5972986 (1999-10-01), Seibert
patent: 6025353 (2000-02-01), Masferrer
patent: 7026346 (2006-04-01), Chen
patent: 7183306 (2007-02-01), Shirai
patent: 7576116 (2009-08-01), Chen
patent: 2002/0032238 (2002-03-01), Priepke
patent: 2003/0162824 (2003-08-01), Krul
patent: 2003/0236294 (2003-12-01), Chen et al.
patent: 2004/0116475 (2004-06-01), Shirai et al.
patent: 2006/0079566 (2006-04-01), Chen
patent: 2006/0142368 (2006-06-01), Chen et al.
patent: 2008/0146815 (2008-06-01), Chen et al.
patent: 2008/0269309 (2008-10-01), Chen
patent: 431943 (1991-06-01), None
patent: 444945 (1991-09-01), None
patent: 554829 (1993-08-01), None
patent: 418845 (1997-03-01), None
patent: 1512396 (2005-03-01), None
patent: 120841 (2007-07-01), None
patent: 95/15315 (1995-06-01), None
patent: 96/41626 (1996-12-01), None
patent: 03/086287 (2003-10-01), None
patent: 2005/044130 (2005-05-01), None
patent: 2008/130669 (2008-10-01), None
Notice of Allowance from U.S. Appl. No. 10/409,502 dated Oct. 25, 2005.
Response from U.S. Appl. No. 10/409,502 dated Aug. 17, 2005.
Office action from U.S. Appl. No. 10/409,502 dated Feb. 17, 2005.
Response from U.S. Appl. No. 10/409,502 dated Dec. 16, 2004.
Office action from U.S. Appl. No. 10/409,502 dated Jul. 16, 2004.
Office action from U.S. Appl. No. 10/957,925 dated Mar. 30, 2007.
Response from U.S. Appl. No. 10/957,925 dated Jan. 4, 2007.
Office action from U.S. Appl. No. 10/957,925 dated Oct. 4, 2006.
Written Opinion from International Application No. PCT/US04/32723 dated Jul. 25, 2005.
International Search Report from International Application No. PCT/US04/32723 dated Jul. 25, 2005.
International Search Report from International Application No. PCT/US03/10738 dated Jan. 21, 2004.
Written Opinion from International Application No. PCT/US03/10738 dated Jun. 4, 2004.
Supplemental Search Report from European Application No. 03723936 dated Dec. 2, 2005.
Supplemental Search Report from European Application No. 04816902 dated Jul. 26, 2007.
Examination Report from European Application No. 03723936 dated Oct. 30, 2007.
Office action from Chinese Application No. 0661255 dated Dec. 7, 2007.
Birmingham et al., “Autophagy controlsSalmonellainfection in response to damage to theSalmonella-containing vacuole”, J Biol Chem 281, pp. 11374-11383 (2006).
HCAPLUS 1994:8589, CAS Registry No. 151506-47-7, (1994).
Product catalog, Cayman Chemical Company, item 10008005 (OSU03012), May 2006, 3 pgs, (2006).
Gutierrez et al., “Autophagy is a defense mechanism inhibiting BCG and Mycobacterium tuberculosis survival in infected macrophages”, Cell 119, pp. 753-766 (2004).
Buchdunger et al., “Inhibition of the Abl Protein-Tyrosine Kinase in Vitro and in Vivo by a 2-Phenylaminopyrimidine Derivative” Cancer Research 56, 100-104, (1996).
Devleeschauwer et al., “Remarkably Mild and Simple Preparations of Sulfinates, Sulfonyl Chlorides and Sulfonamides from Thioanisoles”, Synlett, Thieme International, Stuttgart, DE, No. 4, 375-377 (Apr. 1997).
Groesch et al. (2001): STN International CAPLUS database, Columbus (Ohio), Accession No. 2001: 912333.
Johnson et al., “A novel celecoxib derivative, OSU03012, induces cytotoxicity in primary CLL cells and transformed B-cell lymphoma via a caspase and Bcl-2 independent mechanism”, Blood First Edition Paper, prepublished online Sep. 28, 2004.
Nakagawa et al., “Autophagy defends cells against invading group A Streptococcus”, Science 306, pp. 1037-1040 (2004).
Penning et al., “Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-5[4-methylpheny1)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide (SC-58635, celecoxib),” J Med Chem, 40: 1347-65 (1997).
Yacoub et al., “OSU-03012 Promoted Caspase-independent but PERK-, Cathepsin B-, BID-, and AIF-dependent killing of transformed cells”, Molecular Pharmacology Fast Forward, first published on Apr. 18, 2006.
Yacoub et al., “OSU-03012 regulates cell growth in vitro of human glioma cells”, Abstract from http://www.dominican.edu/query
cur/display—ncur.php?id+2387, printed Jul. 24, 2007, 2 pgs.
Zhao et al., “The phospohonositide-dependent kinase-1 inhibitor, OSU-03012, prevents Y-box binding protein-1 (YB-1) from inducing epidermal growth factor receptor (EGFR)”, Molecular Pharmacology Fast Forward, published on Jun. 26, 2007.
Response from U.S. Appl. No. 10/957,925 dated Aug. 18, 2006.
Office action from U.S. Appl. No. 10/957,925 dated Apr. 18, 2006.
Office action from U.S. Appl. No. 11/354,528 dated Jan. 31, 2008.
Response to Restriction from U.S. Appl. No. 11/864,612 dated Jan. 20, 2009.
Notice of Allowance from U.S. Appl. No. 11/864,612 dated Apr. 10, 2009.
Office action from U.S. Appl. No. 12/118,788 dated Jul. 26, 2010.
Amendment from U.S. Appl. No. 12/118,788 dated Oct. 21, 2010.
Notice of Allowance from U.S. Appl. No. 12/118,788 dated Dec. 1, 2010.
Office action from U.S. Appl. No. 12/476,772 dated Sep. 7, 2010.
Amendment from U.S. Appl. No. 12/476,772 dated Dec. 7, 2010.
Amendment from U.S. Appl. No. 12/476,772 dated Dec. 20, 2010.
Office action from Canadian Application No. 2,566,846 dated Dec. 2, 2010.
Office action from Chinese Application No. 200480036007.3 dated Dec. 7, 2007.
Amendment from Chinese Application No. 200480036007.3 dated May 30, 2008.
Office action from Chinese Application No. 200480036007.3 dated Jul. 18, 2008.
Amendment from Chinese Application No. 200480036007.3 dated Sep. 24, 2008.
Office action from Chinese Application No. 200480036007.3 dated Nov. 7, 2008.
Amendment from Chinese Application No. 200480036007.3 dated Mar. 20, 2009.
Communication from European Application No. 10005407.1 dated Aug. 18, 2010.
Office action from Indian Application No. 1131/CHENP/2006 dated Sep. 15, 2010.
Office action from Japanese Application No. 2006-534245 dated Jul. 28, 2010.
Response from Japanese Application No. 2006-534245 dated Oct. 27, 2010.
Office action from Japanese Application No. 2006-534245 dated Nov. 18, 2010.
Ahlstrom et al., “CYP2C9 structure-metabolism relationships: Optimizing the metabolic stability of COX-2 inhibitors”, J of Medicinal Chemistry, vol. 50, No. 18, pp. 4444-4442, Sep. 6, 2007.
Fustero et al., “Improved regioselectivity in pyrazole formation through the use of fluorinated alcohols as solvents: Synthesis and biological activity of fluorinated tebufenpyrad analogs”, J. of Organic Chemistry, vol. 73, No. 9, pp. 3523-3529, May 2, 2008.
Habeeb et al., “Design and Synthesis of Celecobix and Rofecobix analogues as selective cyclooxygenase-2 (COX-2) Inhibitors: Replacement of Sulfonamide and Methylsulfonyl pharmacophores by an Azido Bioisostere”, J. of Medicinal Chemistry, American Chemical Society, Washington, US, vol. 44, No. 1, pp. 3039-3042, Jan. 1, 2001.
Singh et al., “Methanesulfonamide group at position-4 of the C-5-phenyl ring of 1,5-diarylpyrazole affords a potent class of cyclooxygenase-2 (COX-2) inhibitors”, Bioorganic and Medicinal Chemistry Letters, vol. 14, No. 7, pp. 1683-1688, Apr. 2004.
Sloop et al., “Synthesis of fluorinated heterocycles”, J. of Fluorine Chemistry, Elsevier, vol. 118, No. 1-2, pp. 135-147, Dec. 1, 2002.
Sosnovikikh et al., “2-Polyfluoroalkylchromones”,
Chen Ching-Shih
Chiu Hao-Chieh
Gunn John S.
Schlesinger Larry S.
Wang Dasheng
Calfee Halter & Griswold LLP
Habte Kahsay T
The Ohio State University Research Foundation
LandOfFree
Anti-infective agents against intracellular pathogens does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Anti-infective agents against intracellular pathogens, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-infective agents against intracellular pathogens will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4299968